Tipranavir is a synthetic, non-peptidic HIV-1 protease inhibitor used as an antiretroviral pharmaceutical ingredient. It belongs to the protease inhibitor class and was developed for treatment of HIV-1 infection, particularly in treatment-experienced patients with resistance to multiple protease inhibitors. Tipranavir is administered with ritonavir as a pharmacokinetic boosting agent. PubChem identifies Tipranavir by CAS 174484-41-4, molecular formula C₃₁H₃₃F₃N₂O₅S, and molecular weight 602.7 g/mol.
Tipranavir is a sulfonamide-containing, non-peptidic protease inhibitor. Unlike peptidomimetic protease inhibitors, its chemical structure incorporates a dihydropyrone-containing scaffold and trifluoromethyl-substituted pyridine sulfonamide group.
The pharmaceutical substance is a single stereoisomer with the 1R,6R configuration, making stereochemical control an important part of API manufacturing and analytical characterization.
Tipranavir has the molecular formula C₃₁H₃₃F₃N₂O₅S and molecular weight 602.7 g/mol. It is identified by FDA GSRS UNII ZZT404XD09. The active moiety is also associated with the disodium salt, but the free Tipranavir substance should not be confused with Tipranavir disodium when defining an API specification.
The compound contains two defined stereocenters, and PubChem records the defined stereochemical configuration of the pharmaceutical substance.
Tipranavir inhibits HIV-1 protease, an enzyme required for processing viral Gag and Gag-Pol polyproteins. Inhibition of this processing prevents the formation of mature infectious HIV virions. FDA documentation describes Tipranavir as a non-peptidic HIV-1 protease inhibitor.
Tipranavir API is associated primarily with antiretroviral formulations used for:
The FDA label describes Aptivus as an oral formulation containing Tipranavir and specifies administration with ritonavir.
Quality control for Tipranavir API should address identity, assay, stereochemical integrity, organic impurities, residual solvents, elemental impurities, water content and other process-related impurities according to the applicable registered specification.
Publicly accessible authoritative sources reviewed for this page establish the chemical identity and physicochemical characteristics of Tipranavir, but do not provide a current universal public API release specification with numerical limits for every CMS field. Therefore, numerical limits such as assay, individual impurities, total impurities and water should not be invented or presented as universal pharmacopoeial requirements.
For commercial API release, the applicable approved specification, customer specification and validated analytical methods should take precedence.
Tipranavir manufacturing requires controlled synthetic processing and purification to obtain the required chemical and stereochemical quality. Particular attention is required for the defined stereochemistry because Tipranavir is supplied as a specific stereoisomer.
Manufacturing controls can include chromatographic assay and impurity profiling, spectroscopic identification, residual-solvent testing, elemental-impurity assessment and appropriate solid-state/physical characterization.
Tipranavir is described by FDA as a white to off-white to slightly yellow solid. It is freely soluble in dehydrated alcohol and propylene glycol and insoluble in aqueous buffer at pH 7.5.
PubChem reports a melting point of approximately 86–89°C and specific optical rotation of approximately +20° at 25°C/D in ethanol. These are reference physicochemical values and should not automatically be entered as API release specifications.
Tipranavir API should be packaged in suitable pharmaceutical-grade, well-closed containers that protect the material from moisture, contamination and unsuitable environmental exposure. Storage conditions should follow the manufacturer's validated stability data and approved API specification.
A commercial Tipranavir API supply package may include:
A reliable Tipranavir API manufacturer should maintain stringent controls over chemical purity, stereochemical integrity, process-related impurities and batch-to-batch consistency. Validated analytical methods and appropriate pharmaceutical quality systems are essential for producing consistent material for regulated pharmaceutical manufacturing.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Melting Point | 86–89°C |